RenalGuard

Real-time hydration therapy to reduce acute renal failure after contrast administration (PC-AKI).

RenalGuard is a liquid balancing system that measures the amount of urine exactly and automatically introduces the same volume in real time as a replacement liquid. Patients who are connected to the RenalGuard system receive a diuretic (furosemide) before the start of the procedure, which ensures that a high urine flow is achieved. This is believed to dilute the contrast medium needed and flush it through the kidney faster. In addition to use in the cardiac catheter laboratory, there are other areas of application for RenalGuard in vascular surgery, angiology and interventional radiology. Studies have shown that the use of RenalGuard during a procedure in the cardiac catheter laboratory with contrast medium significantly reduces kidney damage.1,2,3,4

RenalGuard

Slider

RenalGuard® is CE certified and sold worldwide. Kaneka Pharma Europe N.V. is the new exclusive distributor for RenalGuard Solutions, Inc. products in Europe, the Middle East and Africa.

 

For further information:
Slider

Slider

References:

 
  1. Marenzi G, Ferrari C, Marana I, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv. 2012;5(1):90‐97. doi:10.1016/j.jcin.2011.08.017
  2. Briguori C, Visconti G, Focaccio A, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011;124(11):1260‐1269. doi:10.1161/CIRCULATIONAHA.111.030759
  3. Usmiani T, Andreis A, Budano C, et al. AKIGUARD (Acute Kidney Injury GUARding Device) trial: in-hospital and one-year outcomes. J Cardiovasc Med (Hagerstown). 2016;17(7):530‐537. doi:10.2459/JCM.0000000000000348
  4. Rihal CS, Kashani KB. Prevention of Acute Kidney Injury With the RenalGuard System in Patients Undergoing Transcatheter Aortic Valve Replacement: The PROTECT-TAVI Trial (PROphylactic effecT of furosEmide-induCed diuresis with matched isotonic intravenous hydraTion in Transcatheter Aortic Valve Implantation). JACC Cardiovasc Interv. 2015;8(12):1605‐1607. doi:10.1016/j.jcin.2015.08.007